tickrz reports
  
tickrz rank
B
Gilead Sciences Inc (GILD)
Healthcare | Biotechnology
CEO: John F. Milligan
Employees: 8000
gilead.com
FACTOR RANKINGSFACTOR SCREENER 
Pure Value Rank105Dividend RankNOT AVAILABLE
Moat Rank58Financial Strength Rank231
Growth Rank4Momentum Rank474
DIVIDEND ANALYSIS
Dividend Yield3%
Payout Ratio20.96%
3 yr Dividend GrowthN/A
VALUATION RATIOS
P/E Ratio6.71x
P/B Ratio4.15x
P/S Ratio2.91x
EV/EBITDA Ratio4.22x
FINANCIAL STRENGTH
Piotroski F-Score4
Debt-to-Equity126%
Interest Coverage17.29x
MOAT
ROE72.25%
ROIC90.73%
Net Margin44.53%
GROWTH
5 yr EPS Growth41.14%
5 yr SPS Growth29.07%
5 yr BPS Growth26.37%
Gilead Sciences Inc achieves a strong Pure Value rank with its low valuation multiples
 tickrz summary
Gilead Sciences Inc receives a B ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.
 value
 pure value ranking Warren Buffett ranking
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Gilead Sciences Inc's valuation score is comprised of a P/E ratio of 6.7x, a P/B ratio of 4.2x, a P/S ratio of 2.9x, and an EV/EBITDA ratio of 4.2x. Gilead Sciences Inc ranks 105 out of the S&P 500 constituents on valuation--a relatively strong score.Gilead Sciences Inc ranks 39 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a strong score, meaning it ranks highly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Gilead Sciences Inc warrants further investigation.

 quality
 moat financial strength
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is strong. Gilead Sciences Inc appears to have a durable competitive advantage within the Healthcare sector. Gilead Sciences Inc has a Piotroski F Score of 4 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 17.29x, a debt/equity ratio of 126% and a Moat Rank of 58 translate to an average Financial Strength score.


 momentum
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors.The company has seen its stock fall by -19.31% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 474. Based on its 12 month stock performance, Gilead Sciences Inc will not appeal to momentum investors.

 yield
 value + yield
Unfortunately we do not have enough data to provide a dividend ranking for Gilead Sciences Inc.

 growth
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the top third of S&P 500 companies. Its 41.1% 5 year annualized EPS growth, 29.1% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 26.4% speak to its impressive growth ranking.

Gilead Sciences Inc (GILD)
Healthcare | Biotechnology
CEO: John F. Milligan
Employees: 8000
gilead.com


tickrz rank
B

VALUATION RATIOS
P/E Ratio6.71x
P/B Ratio4.15x
P/S Ratio2.91x
EV/EBITDA Ratio4.22x
DIVIDEND ANALYSIS
Dividend Yield3%
Payout Ratio20.96%
3 yr Dividend GrowthN/A
FINANCIAL STRENGTH
Piotroski F-Score4
Debt-to-Equity126%
Interest Coverage17.29x
MOAT
ROE72.25%
ROIC90.73%
Net Margin44.53%
GROWTH
5 yr EPS Growth41.14%
5 yr SPS Growth29.07%
5 yr BPS Growth26.37%

TICKRZ RANK
Gilead Sciences Inc receives a B ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.

PURE VALUE
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Gilead Sciences Inc's valuation score is comprised of a P/E ratio of 6.7x, a P/B ratio of 4.2x, a P/S ratio of 2.9x, and an EV/EBITDA ratio of 4.2x. Gilead Sciences Inc ranks 105 out of the S&P 500 constituents on valuation--a relatively strong score.

WARREN BUFFETT RANKING
Gilead Sciences Inc ranks 39 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a strong score, meaning it ranks highly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Gilead Sciences Inc warrants further investigation.

MOAT
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is strong. Gilead Sciences Inc appears to have a durable competitive advantage within the Healthcare sector.

FINANCIAL STRENGTH
Gilead Sciences Inc has a Piotroski F Score of 4 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 17.29x, a debt/equity ratio of 126% and a Moat Rank of 58 translate to an average Financial Strength score.

MOMENTUM
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors.The company has seen its stock fall by -19.31% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 474. Based on its 12 month stock performance, Gilead Sciences Inc will not appeal to momentum investors.

VALUE + YIELD
Unfortunately we do not have enough data to provide a dividend ranking for Gilead Sciences Inc.

GROWTH
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the top third of S&P 500 companies. Its 41.1% 5 year annualized EPS growth, 29.1% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 26.4% speak to its impressive growth ranking.